$NKTR News Article - Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
https://marketwirenews.com/news-releases/nekt...58477.html